GERN

Business Context and Reporting Period

Company: Geron Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2010
Business Overview: Geron is a biopharmaceutical company developing first-in-class therapies for cancer and chronic degenerative diseases. Its primary platforms include telomerase inhibitors (Imetelstat), telomerase vaccines (GRNVAC1), receptor-targeting peptides for blood-brain barrier penetration (GRN1005), and human embryonic stem cell (hESC) therapies (GRNOPC1 for spinal cord injury). The company has no approved commercial products and relies on licensing and collaboration revenues.

Key Financial Metrics

Liquidity: The company held approximately $221.3 million in cash and marketable securities as of December 31, 2010. Management estimates these resources are sufficient to fund operations through at least December 2012.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 106% to $3.6 million, driven primarily by collaboration revenues from GE Healthcare and license fees.
• Net Loss Expansion: Net loss increased 59% to $111.4 million. This was primarily due to a one-time $35 million charge for acquired in-process research and development (IPR&D) related to the Angiochem license and increased R&D spending for clinical trials.
• Strategic Acquisition: In December 2010, Geron entered an exclusive license agreement with Angiochem for GRN1005 (a peptide-conjugated paclitaxel), resulting in the $35 million IPR&D expense and a stock issuance obligation of $27.5 million.
• Clinical Progress: Initiated four Phase 2 trials for Imetelstat (NSCLC, Breast Cancer, Multiple Myeloma, Essential Thrombocythemia) and began the first FDA-approved Phase 1 trial for GRNOPC1 (spinal cord injury) in October 2010.

Guidance, Outlook, and Risks

Outlook: Geron anticipates continued operating losses as it advances clinical trials. The company expects R&D expenses to increase due to the expansion of Imetelstat and GRNOPC1 trials and the development of GRN1005. No specific financial guidance was provided for 2011.

Management Commentary: Management highlighted the successful initiation of multiple Phase 2 trials and the first-in-human hESC trial. They emphasized the need for additional capital to sustain operations beyond late 2012 if revenues do not materialize.

Key Risks:

• Capital Requirements: The company has a history of losses and will require substantial additional capital. Failure to secure funding could force the curtailment of operations.
• Regulatory & Clinical Uncertainty: All product candidates are in early-stage development. Clinical trials may fail to demonstrate safety or efficacy, and regulatory approval is uncertain.
• Intellectual Property: The company faces ongoing patent oppositions and interference proceedings, particularly regarding hESC technologies in Europe and telomerase vaccines.
• Legal Proceedings: A securities class action lawsuit was filed in December 2010 (voluntarily dismissed in February 2011) and shareholder derivative suits were filed in early 2011 regarding financial disclosures.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $221 million cash balance against projected burn rates for 2011 and 2012, given the lack of product revenue.
• Angiochem Transaction: Confirm the valuation and strategic fit of the $35 million IPR&D charge and the subsequent stock issuance to Angiochem.
• Clinical Trial Enrollment: Monitor patient enrollment rates and safety data for the four new Imetelstat Phase 2 trials and the GRNOPC1 Phase 1 trial.
• Patent Status: Review the status of ongoing European patent oppositions regarding hESC and telomerase technologies, which could impact commercial exclusivity.
• Legal Exposure: Track the status of the shareholder derivative lawsuits filed in early 2011 regarding financial condition disclosures.